Pharmaceutical company AbbVie has increased its annual profit forecast, citing improved sales from newer autoimmune treatments. The company now expects adjusted earnings of $12.09-$12.29 per share for 2025, up from the previous range. However, the revised guidance does not take into account potential changes in trade policies, including tariffs affecting the pharmaceutical sector.
Source: https://www.bloomberg.com/news/articles/2025-04-25/abbvie-lifts-profit-guidance-as-newer-drugs-drive-sales-beat